Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

Running, not enrolling

Conditions studied: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver

In brief

The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of identifying high-risk patients with advanced fibrosis who should be prioritized for specialty referral

Key facts

Study ID

NCT04595474

Run by

Joslin Diabetes Center

People needed

533

Starts

2021-01-14

Expected to finish

2026-12-30

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is male or female
• Subject age between 18-75 years old
• Subject with an established diagnosis of T1D for at least three months prior to screening

You may not qualify if…

• Subject is pregnant or lactating
• Subject has an active malignancy
• Subject with secondary causes of fatty liver including history of any of the following:
• Hepatitis B or C virus infection
• Wilson's disease
• Lipodystrophy
• Abetalipoproteinemia
• Current or previous use of any of the following medication: amiodarone, tamoxifen, methotrexate,corticosteroids (e.g. Prednisone), or Valproate
• Male subject consuming >30 g of alcohol per day or female subject consuming >20 g of alcohol perday

Where it is running

• Joslin Diabetes Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.